Pancreatic Cancer Research

ResearcherUniversity of California San DiegoActive in the last 2 years

Jonathan Weitz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0216-7990; OpenAlex author ID A5039105612; NIH RePORTER profile ID 14345011. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
2
Labs led
1
Collaborators
23
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 1 grant · 2025: 1 paper · 2026: 3 papers, 1 grant

Papers 8

  1. Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". Co-author DOI 10.1016/j.jpet.2026.104305↗
  2. Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug. Co-author DOI 10.1073/pnas.2511733123↗
  3. Metabolic Salvage and Acyl-chain Remodeling Support Glycosphingolipid Synthesis within the PDAC Tumor Microenvironment Co-author DOI 10.64898/2026.04.14.718544↗
  4. Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jpet.2025.103573↗
  5. Pancreatic ductal adenocarcinoma induces neural injury that promotes a transcriptomic and functional repair signature by peripheral neuroglia. Co-author DOI 10.1038/s41388-023-02775-7↗
  6. Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-22-3645↗
  7. Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-23-1313↗
  8. Using Organotypic Tissue Slices to Investigate the Microenvironment of Pancreatic Cancer: Pharmacotyping and Beyond. Co-author DOI 10.3390/cancers13194991↗

Grants 2

  1. Targeting CDK4/6 as an interception strategy for intraductal papillary mucinous neoplasia K01CA297135↗
  2. The role of sympathetic nerve associated macrophages during pancreatic adenocarcinoma progression F32CA265052↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew M. Lowy · 8 shared papers, 2021–2026 · strength 1.67
  2. Hervé Tiriac · 7 shared papers, 2021–2026 · strength 1.51
  3. Paul A. Insel · 2 shared papers, 2025–2026 · strength 0.49
  4. Elena Tomás Bort · 2 shared papers, 2025–2026 · strength 0.49
  5. Peter James McCormick · 2 shared papers, 2025–2026 · strength 0.49
  6. Krishna Sriram · 2 shared papers, 2025–2026 · strength 0.49
  7. Richard Philip Grose · 2 shared papers, 2025–2026 · strength 0.49
  8. Cristina Salmerón · 2 shared papers, 2025–2026 · strength 0.49
  9. Satoshi Ogawa · 2 shared papers, 2023–2026 · strength 0.41
  10. Dannielle D. Engle · 2 shared papers, 2023–2026 · strength 0.41
  11. Tatiana Hurtado de Mendoza · 2 shared papers, 2021–2023 · strength 0.33
  12. Casie S. Kubota · 1 shared paper, 2026 · strength 0.26
  13. Christian M. Metallo · 1 shared paper, 2026 · strength 0.26
  14. Anna Trimble · 1 shared paper, 2026 · strength 0.26
  15. Dafna Bar‐Sagi · 1 shared paper, 2026 · strength 0.22
  16. Laura Antonucci · 1 shared paper, 2026 · strength 0.22
  17. Beicheng Sun · 1 shared paper, 2026 · strength 0.22
  18. David W. Dawson · 1 shared paper, 2026 · strength 0.22
  19. Michael Karin · 1 shared paper, 2026 · strength 0.22
  20. Bharti Garg · 1 shared paper, 2023 · strength 0.22
  21. Deepak Rohila · 1 shared paper, 2023 · strength 0.16
  22. Shweta Joshi · 1 shared paper, 2023 · strength 0.16
  23. Kevin Christian Montecillo Gulay · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.